Increasing evidence for skin substitute efficacy in 2021
The year 2021 led to increasing consensus on the role of skin substitutes in closing hard-to-heal wounds.1 The Association for the Advancement of Wound Care (AAWC), along with its members, have continued to strive to fulfil its mission to advance the care of patients with and at-risk of wounds, through contributions to this growing library of evidence.
Promising studies examined non-human grafts that provide extracellular matrix (ECM) structure and composition, while differing in their source and decellularisation processing techniques. These include:
The porcine peritoneum-derived matrix was executed as a 12-person pilot study,4 and FBADM was evaluated in a 226-person randomised controlled trial (RCT).2 FBADM was found to be a faster and more effective treatment for diabetic foot ulcers (DFUs) than standard of care (SOC) alone. Importantly, all products in the skin substitute or cellular and/or tissue-based products space demonstrated safety while others exhibited varying desirable features such as bactericidal activity, low scarring, and improved wound healing.2,3,4,5 Continuing maturation of non-human allograft options promises a broader supply of skin substitute materials with greater patient access.
Register now to continue reading
Thank you for visiting Wound Central and reading some of our peer-reviewed resources for wound care professionals. To read more, please register today. You’ll enjoy the following great benefits:
Access to clinical or professional articles
New content and clinical updates each month